Schrodinger/$SDGR
1D1W1MYTD1Y5YMAX
Capital at risk
About Schrodinger
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
- Ticker
- $SDGR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 850
- Headquarters
- New York, United States
- Website
- www.schrodinger.com
Schrodinger Metrics
BasicAdvanced
$2.2B
-
-$0.74
1.69
-
Price and volume
Market cap
$2.2B
Beta
1.69
52-week high
$31.59
52-week low
$10.95
Average daily volume
1.7M
Financial strength
Current ratio
2.706
Quick ratio
2.616
Long term debt to equity
0.278
Total debt to equity
0.328
Profitability
EBITDA (TTM)
-147.579
Gross margin (TTM)
56.87%
Net profit margin (TTM)
-20.98%
Operating margin (TTM)
-59.24%
Effective tax rate (TTM)
-4.63%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-14.44%
Return on equity (TTM)
-16.18%
Valuation
Price to revenue (TTM)
8.35
Price to book
6.48
Price to tangible book (TTM)
6.57
Price to free cash flow (TTM)
-16.604
Free cash flow yield (TTM)
-6.02%
Free cash flow per share (TTM)
-1.76
Growth
Revenue change (TTM)
8.88%
Earnings per share change (TTM)
-70.30%
3-year revenue growth (CAGR)
10.16%
3-year earnings per share growth (CAGR)
-6.47%
What the Analysts think about Schrodinger
Analyst ratings (Buy, Hold, Sell) for Schrodinger stock.
Analyst projections of the future price of Schrodinger stock.
Bulls say / Bears say
Schrödinger is shifting towards a more capital-light therapeutics model. Tectora raised $55 million from NEA and RA Capital to advance two early-stage programmes, while Schrödinger retained equity and potential milestone and royalty exposure without funding all development itself. (InvestorPlace)
The company has substantial financial flexibility to develop its platform and pursue partnerships: Q2 ended with $418.8 million in cash and marketable securities. Its physics-based FEP+ research also reported testing more than 230 compounds across five challenging targets, supporting the case that the platform offers differentiated scientific value. (Last10K, MarketChameleon)
Core software revenue fell 10% year on year to $32.5 million in Q2 as the shift to hosted licensing affected near-term revenue recognition. Software gross margin also fell to 71%, from 76% a year earlier. (Last10K)
The $6 million Q2 net profit was not evidence of recurring profitability: other income included a $48.9 million gain linked largely to Eli Lilly’s Ajax acquisition. Operating expenses were $74 million, above the quarter’s $58.9 million revenue. (Last10K)
Drug-discovery revenue remains lumpy and milestone-dependent: Q2’s rise to $23 million from $13.9 million was mainly due to a $10 million Ajax milestone, which also drove the higher 2026 guidance. Most pipeline assets remain preclinical, leaving future milestones and royalties uncertain. (Last10K, Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Schrodinger Financial Performance
Revenues and expenses
Schrodinger Earnings Performance
Company profitability
Upcoming events
No upcoming events
Schrodinger News
AllArticlesVideos
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire7 days ago
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
Business Wire2 weeks ago
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
Business Wire3 weeks ago
Funds containing Schrodinger
AllUSDEURGBP
Fund name | Fund size | $SDGR weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.19% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.19% |
iShares Healthcare Innovation£DRDR | £1B | 0.19% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.10% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.